pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 18·1 min read
save

Prepping for peptides

It wasn’t too many years ago when we were busy theorizing about the market opportunity for GLP-1 weight loss drugs. Now, the big question is the moneymaking potential for other peptides that might soon move ...

Jun 18, 2026·read at Endpoints ↗

June 18, 2026 10:58 AM EDT Health Tech Prep­ping for pep­tides Shelby Livingston Health tech correspondent It wasn’t too many years ago when we were busy the­o­riz­ing about the mar­ket op­por­tu­ni­ty for GLP-1 weight loss drugs. Now, the big ques­tion is … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
76 words · retrieved Jun 18
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
GLP-1 receptor2Obesity2

related stories

  • Jun 5Texas AG investigating energy drinksSTAT
  • Jun 4STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and moreSTAT
  • Jun 3What it will take for more employer GLP-1 coverageEndpoints
  • Jun 3STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and moreSTAT
  • Jun 1CDC says containing the spread of Ebola is top prioritySTAT